Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review

BACKGROUND: In evaluation of the clinical benefit of a new targeted agent in a phase 3 trial enrolling molecularly selected patients with advanced non-small cell lung cancer (NSCLC), overall survival (OS) as an endpoint seems to be of limited use because of a high level of treatment crossover for et...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, Katsuyuki, Kato, Yuka, Leighl, Natasha, Takigawa, Nagio, Gaafar, Rabab Mohamed, Kayatani, Hiroe, Hirata, Taizo, Ohashi, Kadoaki, Kubo, Toshio, Tabata, Masahiro, Tanimoto, Mitsune, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361736/
https://www.ncbi.nlm.nih.gov/pubmed/25775395
http://dx.doi.org/10.1371/journal.pone.0121211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361736/
https://www.ncbi.nlm.nih.gov/pubmed/25775395
http://dx.doi.org/10.1371/journal.pone.0121211

Ejemplares similares